Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Otterson

Showing results (31-40 of 157) with videos related to

Pageof 16
Sort By:
Journal of Oncology|May 24, 2012
Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung CancerWeiqiang Zhao, Cheng C Huang, Gregory A Otterson, et al.
Cancer Management and Research|November 25, 2020
Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced CancersNatasha A Jain, Songzhu Zhao, Lai Wei, et al.
Journal of the National Cancer Institute|November 18, 2004
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancerWenrui Duan, Li Gao, Lawrence J Druhan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2011
Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancerWolfgang Schuette, Maciej J Krzakowski, Bartomeu Massuti, et al.
International Journal of Cancer|November 19, 2009
MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cellsWenrui Duan, Li Gao, Xin Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief reportArkadiusz Z Dudek, Herbert Pang, Robert A Kratzke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancerGregory A Otterson, Miguel A Villalona-Calero, William Hicks, et al.
Lung Cancer (Amsterdam, Netherlands)|December 27, 2011
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)Thierry Jahan, Lin Gu, Robert Kratzke, et al.
Journal of Oncology|May 12, 2011
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancerHoward Burris, Joe Stephenson, Gregory A Otterson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2010
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)Antonius A Miller, Herbert Pang, Lydia Hodgson, et al.
Pageof 16

Showing results (31-40 of 157) with videos related to

Sort By:
Pageof 16
Journal of Oncology|May 24, 2012
Altered p16(INK4) and RB1 Expressions Are Associated with Poor Prognosis in Patients with Nonsmall Cell Lung CancerWeiqiang Zhao, Cheng C Huang, Gregory A Otterson, et al.
Cancer Management and Research|November 25, 2020
Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced CancersNatasha A Jain, Songzhu Zhao, Lai Wei, et al.
Journal of the National Cancer Institute|November 18, 2004
Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancerWenrui Duan, Li Gao, Lawrence J Druhan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 21, 2011
Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancerWolfgang Schuette, Maciej J Krzakowski, Bartomeu Massuti, et al.
International Journal of Cancer|November 19, 2009
MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cellsWenrui Duan, Li Gao, Xin Wu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a brief reportArkadiusz Z Dudek, Herbert Pang, Robert A Kratzke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancerGregory A Otterson, Miguel A Villalona-Calero, William Hicks, et al.
Lung Cancer (Amsterdam, Netherlands)|December 27, 2011
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107)Thierry Jahan, Lin Gu, Robert Kratzke, et al.
Journal of Oncology|May 12, 2011
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancerHoward Burris, Joe Stephenson, Gregory A Otterson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2010
A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602)Antonius A Miller, Herbert Pang, Lydia Hodgson, et al.
Pageof 16